Clover Corporation Limited · ASX:CLV
Clover — Investor Presentation (March 2026)
19 slides from Clover's investor presentation, Mar 24, 2026
Slide 1: 1H FY26 Investor Presentation
1H FY26 Investor Presentation March 2026 CEO Peter Davey CFO Andrew Allibon
Slide 2: Half Year Financial Highlights
Half Year Financial Highlights $44.1m 35.6% Revenue growth has been generated through new customer acquisitions and increased contribution from existing customers. Revenue up $6.5m(pcp) Gross Margin up 850bp (pcp) EBITDA growth underpinned by sales growth and gross margin improvement from new produc
Slide 3: Half Year Operational Highlights
Half Year Operational Highlights • Sustained customer Ecuador – consistent supply of collaboration and product crude oil deliveries qualification, combined with a strong focus on new products, Melody Dairies continuing to are now delivering a more deliver operational benefits and diversified portfol
Slide 4: New Products drive growth & margin improvement
New Products drive growth & margin improvement FY24 • 1H Market demand fell – high inventory and ongoing low birth rates • China moved to algal powders v tuna • 2H Excess inventory exited with improving demand FY25 • 1H Market demand – Western Manufacturers increased global market share • New produc
Slide 5: Financials
Financials 5
Slide 6: Profit and Loss 1H FY26
Profit and Loss 1H FY26 AUD Million 1H 2026 1H 2025 Change • Revenue up $6.5m (pcp) with growth across Revenue ($m) $44.1 $37.6 +$6.5m Europe and ANZ regions • Gross margin improved driven by favourable Gross Profit ($m) $15.7 $10.2 +$5.5m customer & product mix and general manufacturing performance
Slide 7: Cash flow 1H FY26
Cash flow 1H FY26 Cash flow 1H 2026 1H 2025 • Operating cashflow impacted by the deliberate inventory build of crude and Receipts from customers 54,694 37,461 refined oils against strong customer Payments to suppliers and employees (48,893) (27,847) forecasts Interest paid (25) (148) • Plant & Equip
Slide 8: Balance Sheet 31 Jan 2026
Balance Sheet 31 Jan 2026 AUD 1H 2026 1H 2025 Change ($M) • Strong cash position following excellent Cash 10.3 15.4 (5.1) operational performance, offset by working capital growth (inventory levels) Trade Receivables 14.5 14.1 0.4 Inventories 35.0 23.8 11.2 • Higher level of inventory (raw materials
Slide 9: Operational Highlights
Operational Highlights 9
Slide 10: Ecuador facility: fish oil extraction site
Ecuador facility: fish oil extraction site Volume of crude fish oil extracted from Tuna heads continues to deliver 30% of tuna oil requirements. Continuing to negotiate additional supply of tuna heads Resources have increased to support business growth Clover Corporation | Investor Presentation Marc
Slide 11: New Zealand: processing and encapsulating of oils
New Zealand: processing and encapsulating of oils Melody Dairies facility Delivering high-quality Operating at profitable Weekly use by Clover in Pursuing opportunities products with improved levels meeting the manufacturing product to maximise outputs to plant use and efficiency strategic investmen
Slide 12: CholineXcel®
CholineXcel® • CholineXcel® is a unique flowable powder • Samples have been presented to selected customers • Intellectual Property processes continue with an outcome expected in July 2026 • 1H packaging formats and fill rates continue to be worked on for optimum outputs • Customer product trials (n
Slide 13: DHA & ARA Growth
DHA & ARA Growth DHA Growth (Omega 3) ARA Growth (Omega 6) • ARA included in infant formula • DHA is an element of Omega 3, is a key cell-membrane utilised in Human Nutrition component to regulate products, contributing to brain inflammation, immunity, and development, eye and neural brain function
Slide 14: Premneo Update
Premneo Update Clover’s unique DHA emulsion is clinically proven to increase the IQ of preterm infants Clinical trial in India is planned Regulatory assistance is progressing for the Singapore and Canadian market A 2nd round of Clinical Experts have reviewed information required for EU Regulatory ap
Slide 15: Strategy and outlook
Strategy and outlook 15
Slide 16: Priorities
Priorities 1 Further R&D investment to support product development to expand the portfolio and market offering 2 Continued vertical integration into the supply chain to deliver quality, cost efficiency and availability of ingredients and production 3 Pursuit of alternative applications with new prod
Slide 17: FY26 Outlook
FY26 Outlook • The Board anticipates that the positive momentum from the first half of FY26 will carry forward, resulting in a stronger second half, based on current demand forecasts. • • This outlook assumes that geopolitical tensions will not worsen and supply chains will remain stable, ensuring b
Slide 18: Board members
Board members Rupert Harrington Peter Davey Toni Brendish Chair Managing Director & CEO Non-Executive Director Ian Glasson Dr. Simon Green Fiona Pearse Non-Executive Director Non-Executive Director Non-Executive Director Clover Corporation | Investor Presentation March 2026 18
Slide 19: Q&A
Q&A 19